Eve Investments Ltd

Energy Ventures initiates permitting process for Aurora with NRC submission

no_picture_pai.jpg

Energy Ventures (ASX: EVE) has provided the U.S. Nuclear Regulatory Commission (NRC) with a notice of intent to submit a source material facility licence application.

The notice initiates the permitting process for the proposed development of a uranium processing plant and tailings management facility at the company’s Aurora Uranium Project in southeast Oregon.

Energy Ventures will now progressively work towards additional technical detail and project design over the next 12 months in preparation of the final source material facility licence application.

The Aurora Project comprises a conventional open pit mine and associated infrastructure which will require a range of permits and other authorisations from various state and federal agencies. 

Energy Ventures will begin baseline environmental studies at the project site to prepare an Environmental Impact Statement and support applications for other permits. 

Last month the company completed a $1.6 million non-renounceable rights issue to fund the ongoing technical assessment of Aurora.

In January, Energy Ventures released the initial metallurgical results for the project, showing the potential for efficient removal of internal waste through scrubbing and screening, with minimal uranium loss.

This allows for the mineralisation to be bulk mined and upgraded prior to leaching.

Aurora hosts a near surface, flat lying zone of mineralisation, amenable to open pit mining, with a JORC Resource of 38 million pounds of uranium equivalent.

Quick facts: Eve Investments Ltd

Price: $0.01

Market: ASX
Market Cap: $12.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

1 hour, 13 minutes ago

2 min read